var path='https://www.tickertech.net'; function heading(heading) { document.write('
'+heading+' |
'+ ''+ ' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('4/25 - 7:00 AM \; \; | \n'); } if (allow) { document.write('BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 | \n'); } if (allow) { document.write('
4/24 - 10:31 AM \; \; | \n'); } if (allow) { document.write('BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting | \n'); } if (allow) { document.write('
4/22 - 7:00 AM \; \; | \n'); } if (allow) { document.write('BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential | \n'); } if (allow) { document.write('
4/10 - 7:02 AM \; \; | \n'); } if (allow) { document.write('BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer\'s Dementia | \n'); } if (allow) { document.write('
3/25 - 7:00 AM \; \; | \n'); } if (allow) { document.write('BioXcel Therapeutics Announces $25 Million Registered Direct Offering | \n'); } if (allow) { document.write('
3/15 - 7:00 AM \; \; | \n'); } if (allow) { document.write('BioXcel Therapeutics Announces European Patent Office\'s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine | \n'); } if (allow) { document.write('
3/12 - 7:00 AM \; \; | \n'); } if (allow) { document.write('BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023 | \n'); } if (allow) { document.write('
3/1 - 7:00 AM \; \; | \n'); } if (allow) { document.write('BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 | \n'); } if (allow) { document.write('
2/13 - 9:03 AM \; \; | \n'); } if (allow) { document.write('BioXcel Therapeutics Announces Termination of Proposed Public Offering | \n'); } if (allow) { document.write('
2/12 - 7:15 AM \; \; | \n'); } if (allow) { document.write('BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC) | \n'); } if (allow) { document.write('
2/8 - 4:01 PM \; \; | \n'); } if (allow) { document.write('BioXcel Therapeutics Announces Proposed Public Offering | \n'); } if (allow) { document.write('
2/6 - 7:00 AM \; \; | \n'); } if (allow) { document.write('BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA | \n'); } if (allow) { document.write('
2/5 - 7:00 AM \; \; | \n'); } if (allow) { document.write('BioXcel Therapeutics Announces USPTO\'s Allowance of Patent Application for Method of Treating Agitation in Alzheimer\'s Disease Using Oromucosal Formulations of Dexmedetomidine | \n'); } if (allow) { document.write('
\n'); } if (allow) { document.write(' |